Global Tricupsid Valve Repair Market

Global Tricupsid Valve Repair Market

Global Tricupsid Valve Repair Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Tricupsid valve repair is almost always performed due to tricupsid regurgitation and in conjunction with left-sided valve surgery or coronary artery bypass graft. Sole tricupsid valve repairs are rare, due to an increased incidence of complications. The main indication of the repair is secondary tricupsid regurgitation due to annular enlargement, right ventricular remodelling, and advanced left heart diseases.

Market Dynamics: Drivers & Restraints

Rise in the number of cardiovascular surgeries

The rise in the number of cardiac surgeries indeed helps the market to grow during the forecast period. For instance, coronary artery bypass graft (CABG) is the most common major surgical procedure, with around 4,000 heart bypass surgeries performed annually in India and 2,00,000 in the US. 10% of patients with coronary artery disease undergo CABG, with risk factors including bad cholesterol, hypertension, obesity, diabetes, and smoking. India has a 98% success rate for CABG, better than most advanced countries.

Survival rates for CABG patients range from 92% at 5 years to 4% at 40 years. Women have a higher operative mortality rate due to their smaller coronary arteries. India has only 5500 cardiologists, with one cardiologist for 30,000 people.

Furthermore, the global tricupsid valve repair is also driven by various other factors like advancements in surgical techniques and technologies, preference for valve repair over replacement and others helping the market to grow during the forecast period.

Complications associated with the procedures

Tricupsid valve repair, whether surgical or transcutaneous, can lead to various complications, including perioperative bleeding, arrhythmias, heart blockages, heart failure, stroke, infections of the surgical site and valve prosthesis, sepsis, pneumonia, embolisms, renal failure, drug reactions, and prosthetic valve malfunction. These complications are common in any valvular heart procedure.

Segment Analysis

The global tricupsid valve repair market is segmented based on device type, indication, end-user and region.

The annuloplasty from the device type segment accounted for approximately 54.2% of the Tricupsid Valve Repair market share

The annuloplasty from the device type segment accounted for approximately 54.2%. The use of tricupsid annuloplasty is the preferred surgical repair technique, driven by advancements in transcatheter treatment and the development of new Tricupsid annuloplasty rings. This approach is more commonly used in patients with advanced Tricupsid disease and cardiomyopathy, rather than prophylactic interventions.

For instance, in January 2021, Valcare Medical Ltd. developer of transcatheter mitral and Tricupsid valve repair and replacement solutions, stated that it had completed its first-in-human transseptal delivery of the AMEND annuloplasty ring. The transseptal AMEND procedure was performed at the Schulich Heart Centre at Sunnybrook Health Sciences Centre in Toronto, under the Health Canada Special Access Program.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors such as FDA approvals, CE marks, easy availability of technologically advanced items and awareness among patients about valve repair operations or annuloplasty.

For instance, in October 2023, Edwards Lifesciences' EVOQUE gained a CE mark to become the world's first transcatheter Tricupsid replacement valve to be approved.

Moreover, as per the data published by Economic Co-operation and Development (OECD) in 2022, in the U.S., the population aged 65 years or older increased to 16.83% in 2022. Moreover, according to the Population Reference Bureau, the U.S. population is growing older and the gender gap in life expectancy is narrowing down.

Covid 19 Impact Analysis

The COVID-19 pandemic significantly impacted the heart repair sector, reducing the number of heart procedures due to lockdowns and governmental restrictions, and negatively impacting market growth by reducing the use of the annuloplasty system.

Market Segmentation

By Device Type
• Annuloplasty
• Valvuloplasty

By Indication
• Tricupsid Valve Regurgitation
• Tricupsid Valve Stenosis
• Others

By End User
• Hospital
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Corcym, Labcor, Abbott, CroiValve, Edwards Lifesciences, Innoventric, Medtronic, Mitralix, OrbusNeich, TriCares, Venus Medtech among others.

Key Developments

 In May 2023, Abbott announced late-breaking data that added to the body of clinical evidence supporting the benefits of the TriClip transcatheter edge-to-edge repair (TEER) system in treating patients with leaky tricuspid valves. Abbott's TriClip device is a first-of-its-kind, minimally invasive device designed specifically for tricuspid heart valve repair.

Why Purchase the Report?
• To visualize the global tricupsid valve repair market segmentation based on device type, indication, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of tricupsid valve repair market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global tricupsid valve repair market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies